Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

BACKGROUND: Apremilast, a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production. OBJECTIVES: Apremilast’s effect on patient-reported outcomes (PROs) in patients with moderate to severe psoriasis was evaluated in a phase IIb randomized, contro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Strand, Vibeke, Fiorentino, David, Hu, ChiaChi, Day, Robert M, Stevens, Randall M, Papp, Kim A
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3661377/
https://ncbi.nlm.nih.gov/pubmed/23663752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-7525-11-82
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados